Beta amyloid proteins are produced and cleared from the brain as a part of a normal biological process. With advanced age, the clearance of beta amyloid is impaired, beta amyloid proteins aggregate and accumulate into plaques, triggering a cascade of events leading to injury of brain cells, neurodegeneration or neuropathology, and resulting in conditions such as Alzheimer’s disease and cerebral amyloid angiopathy.
Aging is the main risk and driving factor in the development of Alzheimer’s disease, resulting in the current worldwide epidemic of this disease. Alzheon is building a pipeline of oral, beta amyloid-targeting drugs to block this pathological process and treat diseases caused or worsened by beta amyloid deposits.
ALZ-801, our lead drug candidate, is an optimized, oral prodrug of the active molecule tramiprosate containing a naturally occurring amino acid. Tramiprosate has been studied in more than 2,000 Alzheimer’s patients over 18 months of treatment, with a favorable safety profile. We have leveraged this significant dataset in Alzheimer’s patients and uncovered new insights into the efficacy of tramiprosate in genetically-defined subpopulations allowing us to accelerate ALZ-801 into a pivotal Phase 3 clinical program. After confirmation of clinical efficacy and initial approval, ALZ-801 could be developed for all patients with Alzheimer’s disease. Learn about the Underlying Clinical Data of ALZ-801.